Chief Financial Officer · LENZ Therapeutics, Inc. (LENZ)

Daniel Chevallard

FY2024 is the first fiscal year CompBrief holds for Daniel Chevallard as a named executive officer of LENZ Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,063,051

Salary $376,808Stock awards $0

2nd of 4 named executive officers at Lenz Therapeutics by FY2024 total.

4 named officers on file for LENZ Therapeutics, FY2024

Daniel Chevallard’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how LENZ Therapeutics’s whole pay program stands against its peers

  • LENZ Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LENZ→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Daniel Chevallard’s full pay file as a PDF — free

More than this page: up to 10 years of Daniel’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Daniel Chevallard compensation by year

LENZ Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as LENZ Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$376,808
Bonus$0
Stock awards$0
Option awards$2,489,320
Non-equity incentive$196,923
Pension and deferred compensation$0
All other$0
Total$3,063,051

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LENZ Therapeutics, Inc. DEF 14A filed April 28, 2025, accession 0001193125-25-100630, and prior-year filings. Open the filing on EDGAR.

How this page was built: the LENZ Therapeutics, Inc. filed document, accession 0001193125-25-100630. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option200,000—$15.05

Per the Outstanding Equity Awards at Fiscal Year-End table in LENZ Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

6 Form 4 lines since the FY2024 proxy (filed April 28, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-10-30Grant or award derivative—652,063$0.00652,063
2026-03-27Purchase—7,500$8.5712,886
2026-01-02Grant or award derivative—84,200$0.0084,200
2026-01-02Grant or award derivative—14,000$0.0014,000
2025-11-07Purchase—20$22.713,208
2025-11-07Purchase—2,178$22.765,386

The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

LENZ Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Evert SchimmelpenninkPresident and Chief Executive Officer$6,983,510
Daniel Chevallard · this pageChief Financial Officer$3,063,051
Marc OdrichChief Medical Officer$2,039,143
Kimberlee DrapkinFormer Interim President and Chief Executive Officer, and Director$1,097,345

The full LENZ Therapeutics compensation record

free company brief

This page is one person within LENZ Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LENZ Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Daniel Chevallard's compensation dossier · One-time report. No refunds.